Associated Papers
Prevalence and outcomes of cancer and treatment-associated toxicities for patients with ataxia telangiectasia.
Magnarelli A et al.
The Journal of Allergy and Clinical Immunology, 2025
Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients.
von Stedingk K et al.
Scientific Reports, 2021
33674644 (PubMed )
Supplement: 41598_2021_84502_MOESM2_ESM.xlsx › S10_All_Variants
Germline mutation in the TP53 gene in uveal melanoma.
Hajkova N et al.
Scientific Reports, 2018
29769598 (PubMed )
Supplement: 41598_2018_26040_MOESM2_ESM.xlsx › Supplementary_Table_S1
A new ataxia-telangiectasia mutation in an 11-year-old female.
Mortaz E et al.
Immunogenetics, 2017
Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.
Prodosmo A et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2016
p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.
Prodosmo A et al.
The Journal of Clinical Investigation, 2013
Description and validation of high-throughput simultaneous genotyping and mutation scanning by high-resolution melting curve analysis.
Nguyen-Dumont T et al.
Human Mutation, 2009
Variants in the ATM gene associated with a reduced risk of contralateral breast cancer.
Concannon P et al.
Cancer Research, 2008
ATM alterations in childhood non-Hodgkin lymphoma.
Gumy-Pause F et al.
Cancer Genetics and Cytogenetics, 2006
Select a paper to view details